Loading…
GREEN Building Jobs Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
GSA Resilient, Energy Efficient, and Net-Zero Building Jobs Act of 2021 or the GREEN Building Jobs Act of 2021 This bill establishes additional energy-efficiency requirements and programs for federal buildings, with a particular focus on reducing energy and water consumption and greenhouse gas emissions by FY2030 through partnerships with the private sector. Specifically, the bill requires the General Services Administration (GSA) to reduce the following for its facilities by FY2030: average building energy intensity (by at least 25%, relative to FY2018); average potable water consumption intensity (by 54%, relative to FY2007); industrial, landscaping, and agricultural water consumption (by 20%, relative to FY2018); and specified categories of greenhouse gas emissions (by at least 40%, relative to FY2018). The GSA must also implement retrofit projects that reduce the energy consumption of its facilities by at least 35%. Additionally, the GSA must develop plans that ensure that at least 50% of certain facilities offer zero-emission vehicle charging or fueling by December 31, 2030. The bill directs the GSA to work with the private sector through partnerships and financing opportunities in order to implement the bill's requirements. The bill also makes several other changes relating to federal building standards and related authorities, including (1) requiring lessors (i.e., property owners) to disclose data on the utility consumption of leased spaces; (2) requiring the GSA to assess and mitigate area flood risks, based on climate science; and (3) authorizing long-term contracts for federal purchases of renewable energy.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2026 · third_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Read twice and referred to the Committee on Environment and Public Works.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. Issues related to TrumpRX.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medicare/Medicaid
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act S.2761/H.R.5269 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Implementation of Rural Health Transformation Program Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model [CMS-5546-P] Global Benchmark for Efficient Drug Pricing (GLOBE) Model [CMS-5545-P] Reclassification of Nucleic Acid-Based Test Systems for Use with a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments [Docket No. FDA-2025-N-4622] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $40,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Medicare/Medicaid
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Congressional Personalized Medicine Caucus Genetic Testing and Genomic Sequencing for Rare Diseases H.R. 2471 Right Drug Dose Now Act S. 832/H.R. 1492 the Ensuring Pathways to Innovative Cures Act H.R. 946 Optimizing Research Progress Hope and New Cures Act H.R. 1672 Maintaining Investments in New Innovation Act Implementation of the Inflation Reduction Act of 2022 Medicare Drug Price Negotiation Provisions Medicare and Medicaid Programs; CY 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; and Medicare Prescription Drug Inflation Rebate Program (CMS-1832-P) Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2026 Rates; Requirements for Quality Programs; and Other Policy Changes (CMS-1833-P) Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; Quality Reporting Programs; Overall Hospital Quality Star Ratings; and Hospital Price Transparency (CMS-1834-P) Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
Client expense: $47,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832. H.R. 1, One Big Beautiful Bill Act, issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Medicare/Medicaid
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.3684, Infrastructure Investment and Jobs Act (P.L.117-58) implementation; FY2023 Financial Services and General Government Appropriations Act (H.R.8254, S.4685); FY2023 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.8294, S.4670); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 National Defense Authorization Act (H.R.7900, S.4543); H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; FY2023 Consolidated Appropriations Act (H.R.2617).
Client expense: Not reported · Firm income: $50,000
2022 · third_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.3684, Infrastructure Investment and Jobs Act (P.L.117-58) implementation; FY2023 Financial Services and General Government Appropriations Act (H.R.8254, S.4685); FY2023 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.8294, S.4670); FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.8295, S.4659); FY2023 National Defense Authorization Act (H.R.7900, S.4543); FY2022 Budget Reconciliation (H.R.5376).
Client expense: Not reported · Firm income: $50,000
2022 · second_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.3684, Infrastructure Investment and Jobs Act (P.L.117-58) implementation; FY2023 Financial Services and General Government Appropriations; FY2023 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2023 National Defense Authorization Act (H.R.7900); FY2022 Budget Reconciliation (H.R.5376).
Client expense: Not reported · Firm income: $50,000
2022 · first_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.3684, Infrastructure Investment and Jobs Act (P.L.117-58) implementation; FY2022 Consolidated Appropriations Act (H.R.2471, P.L.117-103); FY2023 Financial Services and General Government Appropriations; FY2023 Transportation, Housing and Urban Development, and Related Agencies Appropriations; FY2023 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2023 National Defense Authorization Act; FY2022 Budget Reconciliation (H.R.5376).
Client expense: Not reported · Firm income: $50,000
2021 · fourth_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: FY2022 Financial Services and General Government Appropriations Act (H.R.4345, S.3179); FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.4550, S.3045); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502, S.3062); H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.848, GREEN Act of 2021; S.2118, Clean Energy for America Act; Housing is Infrastructure Act Discussion Draft; H.R.3684, Infrastructure Investment and Jobs Act (P.L.117-58); FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Client expense: Not reported · Firm income: $50,000
2021 · third_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: FY2022 Financial Services and General Government Appropriations Act (H.R.4345); FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act (H.R.4550); FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.4502); H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.848, GREEN Act of 2021; S.2118, Clean Energy for America Act; Housing is Infrastructure Act Discussion Draft; H.R.3684, Infrastructure Investment and Jobs Act; FY2022 Budget Resolution (S.Con.Res.14)/Budget Reconciliation (H.R.5376).
Client expense: Not reported · Firm income: $50,000
2021 · second_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: FY2022 Financial Services and General Government Appropriations Act; FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021; H.R.848, GREEN Act of 2021; S.2118, Clean Energy for America Act; Housing is Infrastructure Act Discussion Draft.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2021 · first_quarter · Environment/Superfund
Legislation and regulations related to higher building standards and green building, including infrastructure: FY2022 Financial Services and General Government Appropriations Act; FY2022 Transportation, Housing and Urban Development, and Related Agencies Appropriations Act; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R.2060, Federal Building Clean Jobs Act; S.832, GREEN Building Jobs Act; H.R.604/S.96, Reopen and Rebuild America's Schools Act of 2021.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office